Ticagrelor is used for reducing the rate of cardiovascular events, including myocardial infarction and stroke, in patients with coronary artery disease or who had acute coronary syndrome. It was first introduced by Astrazeneca Pharmaceuticals Lp in its drug Brilinta on Jul 20, 2011. 13 different companies have introduced drugs containing Ticagrelor.

Ticagrelor Patents

Given below is the list of patents protecting Ticagrelor, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Brilinta	US10300065 (Pediatric)	Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction	Jul 27, 2036	Astrazeneca
Brilinta	US10300065	Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction	Jan 27, 2036	Astrazeneca
Brilinta	US8425934 (Pediatric)	Pharmaceutical compositions	Oct 17, 2030	Astrazeneca
Brilinta	US8425934	Pharmaceutical compositions	Apr 17, 2030	Astrazeneca
Brilinta	USRE46276 (Pediatric)	Triazolo(4,5-D)pyrimidine compounds	Apr 30, 2025 (Expired)	Astrazeneca
Brilinta	USRE46276	Triazolo(4,5-D)pyrimidine compounds	Oct 30, 2024 (Expired)	Astrazeneca
Brilinta	US7265124	Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound	Jul 09, 2021 (Expired)	Astrazeneca
Brilinta	US7265124	Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound	Jul 09, 2021 (Expired)	Astrazeneca
Brilinta	US6525060	Triazolo(4,5-d)pyrimidine compounds	Dec 02, 2019 (Expired)	Astrazeneca
Brilinta	US6525060	Triazolo(4,5-d)pyrimidine compounds	Dec 02, 2019 (Expired)	Astrazeneca
Brilinta	US7250419	Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition	Dec 02, 2019 (Expired)	Astrazeneca
Brilinta	US7250419	Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition	Dec 02, 2019 (Expired)	Astrazeneca
Brilinta	US6251910	1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists	Jul 15, 2018 (Expired)	Astrazeneca
Brilinta	US6251910	1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists	Jul 15, 2018 (Expired)	Astrazeneca

Add above patents to watchlist

Ticagrelor's Family Patents

Full family tree

Ticagrelor Generic API Manufacturers

Several generic applications have been filed for Ticagrelor. The first generic version for Ticagrelor was by Watson Laboratories Inc and was approved on Sep 4, 2018. And the latest generic version is by Invagen Pharmaceuticals Inc and was approved on May 5, 2025.

Given below is the list of companies who have filed for Ticagrelor generic, along with the locations of their manufacturing plants worldwide.